Hemocellular Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Hemocellular Therapeutics Inc. hopes to extend the life of donated human platelets with proprietary freeze-drying technology. Its Stasix, now in preclinical development, is a powdered form of platelets that can be stored at room temperature indefinitely. Once rehydrated, full functionality is restored immediately. Furthermore, Hemocellular claims that since it removes protein plasma before freeze-drying, no cross-matching to patients is necessary.